NanoViricides, Inc. (NNVC) Research

NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.

Market snapshot

Symbol
NNVC
Price
$1.40
Day change
+4.48%
Market cap
$25.0M
P/E ratio
-3.74x
52-week range
0.85-2.23
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • NanoViricides closes $2M direct offering

    NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in lieu of shares, along with accompanying warrants to purchase an additional roughly 1.3 million common shares.

  • NanoViricides closes $2M direct offering

    NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before...

  • Nasdaq semis lead losses as bond yields put pressure on Iran talks

    10am: Nasdaq semiconductors lead early decline  Selling dominated early trading in New York on Tuesday, with tech stocks in the firing line.   The Dow Jones...

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • Evaxion Biotech A/S (EVAX)
  • Generation Bio Co. (GBIO)
  • IGC Pharma, Inc. (IGC)
  • Jasper Therapeutics, Inc. (JSPR)
  • MAIA Biotechnology, Inc. (MAIA)
  • Q32 Bio Inc. (QTTB)
  • SAB Biotherapeutics, Inc. (SABS)

Recent insider activity

  • BONIUK MILTON — trade (0 shares) on 2017-02-21
  • Stephenson Fournier, PLLC — trade (0 shares) on 2017-02-21
  • Diwan Anil — G-Gift (94471 shares) on 2022-08-08
  • Jawadakar Makarand — trade (0 shares) on 2020-02-07
  • Day Mark D. — trade (0 shares) on 2019-06-02

Open NanoViricides, Inc. (NNVC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.